Compare Ford Motor Company (F) vs TG Therapeutics Inc (TGTX) Price & Performance

Ford Motor Company (F) trades at $12.25, up 1.03% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported disappointing Q3 2026 sales with a 6.6% decline due to model phase-outs and supplier issues, though hybrid vehicle adoption shows promise. Financially, Ford maintains strong operating cash flow of $21.28 billion but faces profitability challenges with negative net income margins and declining revenue growth trends.

Ford presents a value opportunity with attractive valuation multiples (P/E 11.21, P/S 0.26) and analyst consensus target of $15.90 offering 30% upside potential. However, investors face significant risks from ongoing sales declines, competitive pressures from Asian automakers, and operational challenges including recent vehicle recalls and production disruptions. The company's transition to hybrids and commercial vehicle strength provides potential catalysts amid current headwinds.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.